Notice biographique de Hugues de Thé, membre de l’Académie des sciences
Zhu, J., Koken, M., Quignon, F., Chelbi-Alix, M., Degos,L., Wang,Z.Y., Chen, Z., de Thé,H. (1997)
Arsenic-induced PML targeting onto nuclear bodies, implications for the treatment of acute
promyelocytic leukemia. PNAS 94, 3978-3983.
Lallemand, V. Guillemin, M.C., Janin, A., Daniel, M.T., Degos, L., Kogan, S., Bishop, M. and de Thé,
H. (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute
promyelocytic leukemia. J. Exp. Med. 189, 1043-1052.
Zhu, J. Gianni, M, Honore, N., Kopf, E., Chelbi-Alix, M., Koken, M., Quignon, F., Rochette-Egly, C., de
Thé, H., (1999) Retinoic acid induces proteasome-dependent degradation of RARA and oncogenic
RARA fusion proteins PNAS 96, 14807-14812.
Lallemand, V., Zhu, J., Puvion, F., Koken, M., Honoré, N., Doubeikovski, A., Duprez, E., Pandolfi,
P.P., Puvion, E., Freemont, P., de Thé, H. (2001) Role of PML sumolation in nuclear body formation,
11S proteasome recruitment and As2O3-induced PML or PML/RARa degradation. J. Exp. Med. 193,
1361-1371.
Zhu, J., Z. Chen, V. Lallemand-Breitenbach, and H. de Thé (2002). How acute promyelocytic
leukaemia revived arsenic. Nature Reviews Cancer 2:705-713
Zhu, J., Zhou, J., Peres, L. , Riaucoux, F., Honoré, N., Kogan, S. H. de Thé (2005) A sumolation site is
essential for PML/RARA transformation Cancer Cell 7 : 143-154.
Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de Thé H. (2005) How patients have benefited
from mouse APL models. Nature Reviews Cancer. 5:821-7.
Zhu, R. Nasr, L. Peres, F. Riaucoux, N. Honoré, C. Berthier, D. Kamashev, J. Zhou, D. Vitoux, C.
Lavau, H. de Thé (2007) RXR is an essential component of the oncogenic PML/RARA complex in vivo
Cancer Cell 12, 23,35.
Lallemand-Breitenbach V., Jeanne M., Benhenda S. and H. de Thé (2008) Arsenic degrades PML or
PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway Nature Cell Biology
10:547-555
R. Nasr, L., M.C. Guillemin, O. Ferhi, H. Soihili, L. Peres, F., C. Berthier, P. Rousselot, V. Lallemand,
B. Gourmel, D. Vitoux, P.P. Pandolfi, C. Rochette-Egly, J. Zhu, H. de Thé (2008) APL leukemia
initiating cell eradication through cooperative RA- and arsenic-triggered PML/RARA degradation
Nature Medicine 14:1333-1342.
Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., Peres, L.,
Berthier, C., Soilihi, H., Raught, B., and de Thé, H. (2010). PML/RARA oxidation and arsenic-binding
initiate the anti-leukemia response of As2O3. Cancer Cell 18(1): 88-98.
Zhang, X. W., X. J. Yan, Z. R. Zhou, F. F. Yang, Z. Y. Wu, H. B. Sun, W. X. Liang, A. X. Song, V.
Lallemand-Breitenbach, M. Jeanne, Q. Y. Zhang, H. Y. Yang, Q. H. Huang, G. B. Zhou, J. H. Tong, Y.
Zhang, J. H. Wu, H. Y. Hu, H. de The, S. J. Chen and Z. Chen (2010). "Arsenic trioxide controls the
fate of the PML-RARalpha oncoprotein by directly binding PML." Science 328, 240-243.
de Thé H., Chen, Z. (2010) APL: novel insights into the mechanisms of cure Nature Reviews Cancer
10, 775-83.
Ablain, J., Leiva, M., Peres, L., Fonsart, J., Anthony, E., and de The, H. (2013). Uncoupling RARA
transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp
Med 210, 647-653.